BridgeBio Joins Nine-Company MFN Drug Pricing Deal With $19.6B Manufacturing Pledge
BBIO sits 57% above its 52-week low of $48.78.
Summary
BridgeBio is one of nine pharma companies that reached most-favored-nation drug pricing agreements with the Trump administration. The deal requires Medicaid to pay prices matching the lowest paid by other developed nations and extends MFN pricing to all new medicines. The nine companies collectively committed $19.6 billion to U.S. manufacturing. BridgeBio said it will not disclose specifics but does not expect future pricing mandates and expects its pricing commitment to exclude medicines approved solely for orphan indications. This follows the earlier Reuters report of a BridgeBio government agreement, adding new details on the multi-company scope and manufacturing investment. The orphan-drug exclusion is a key positive for BridgeBio's pipeline, as many of its therapies target rare diseases.
At the time of this announcement, BBIO was trading at $76.59 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $15B. The 52-week trading range was $48.78 to $93.42. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.